Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels.
作者信息
Mahmood Maryam, Abu Saleh Omar, Sohail M Rizwan
机构信息
Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota, USA
Division of Infectious Disease, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.00019-17. Print 2017 Apr.
Abstract
摘要
相似文献
1
Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels.与超治疗剂量泊沙康唑血药浓度相关的低钾血症和高血压
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.00019-17. Print 2017 Apr.
2
Posaconazole-Induced Pseudohyperaldosteronism.泊沙康唑致假性醛固酮增多症。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02130-17. Print 2018 May.
3
11β-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia.泊沙康唑诱导的高血压和低钾血症中11β-羟基类固醇脱氢酶的抑制作用
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00760-17. Print 2017 Aug.
4
Suspected posaconazole toxicity in a pediatric oncology patient.一名儿科肿瘤患者疑似泊沙康唑中毒。
Pediatr Blood Cancer. 2015 Sep;62(9):1682. doi: 10.1002/pbc.25568. Epub 2015 May 6.
5
Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.泊沙康唑：用于真菌感染的预防和治疗。
Semin Respir Crit Care Med. 2015 Oct;36(5):767-85. doi: 10.1055/s-0035-1562902. Epub 2015 Sep 23.
6
Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.泊沙康唑对急性髓系白血病患者进行预防治疗的药代动力学
J Infect Chemother. 2015 Sep;21(9):663-7. doi: 10.1016/j.jiac.2015.05.011. Epub 2015 Jun 9.
7
Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.血清中泊沙康唑浓度过高相关的视幻觉
Antimicrob Agents Chemother. 2015 Dec 7;60(2):1170-1. doi: 10.1128/AAC.02739-15. Print 2016 Feb.
8
Itraconazole induced hypertension and hypokalemia: Mechanistic evaluation.伊曲康唑引起的高血压和低钾血症：机制评估。
Mycoses. 2018 May;61(5):337-339. doi: 10.1111/myc.12749. Epub 2018 Feb 15.
9
Salvage treatment of histoplasmosis with posaconazole.泊沙康唑对组织胞浆菌病的挽救治疗
J Infect. 2007 Apr;54(4):319-27. doi: 10.1016/j.jinf.2006.05.006. Epub 2006 Jul 7.
10
Posaconazole prophylaxis in hematologic cancer.
N Engl J Med. 2007 May 24;356(21):2215; author reply 2215-8.
引用本文的文献
1
Association of adverse effects with high serum posaconazole concentrations.与高血清泊沙康唑浓度相关的不良反应。
Med Mycol. 2023 Aug 2;61(8). doi: 10.1093/mmy/myad079.
2
Mebendazole Inhibits In Vitro Growth and Decreases Mitochondrion and Cytoskeleton Protein Levels.甲苯咪唑抑制体外生长并降低线粒体和细胞骨架蛋白水平。
J Fungi (Basel). 2023 Mar 21;9(3):385. doi: 10.3390/jof9030385.
3
Antifungal Therapy with Azoles Induced the Syndrome of Acquired Apparent Mineralocorticoid Excess: a Literature and Database Analysis.唑类抗真菌药物治疗诱导获得性表观盐皮质激素过多症：文献和数据库分析。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0166821. doi: 10.1128/AAC.01668-21. Epub 2021 Oct 18.
4
Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism.泊沙康唑血药浓度与假性醛固酮增多症相关。
Clin Infect Dis. 2020 Jun 10;70(12):2593-2598. doi: 10.1093/cid/ciz741.
5
Posaconazole-Induced Hypertension Due to Inhibition of 11-Hydroxylase and 11-Hydroxysteroid Dehydrogenase 2.泊沙康唑因抑制11β-羟化酶和11β-羟类固醇脱氢酶2而导致高血压。
J Endocr Soc. 2019 Jun 6;3(7):1361-1366. doi: 10.1210/js.2019-00189. eCollection 2019 Jul 1.
6
Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis.泊沙康唑缓释片在合并侵袭性曲霉病和毛霉病患者中的药代动力学/药效学研究
Ther Clin Risk Manag. 2019 Apr 24;15:589-595. doi: 10.2147/TCRM.S203625. eCollection 2019.
7
Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents.长期应用唑类抗真菌药物相关的不良反应。
Drugs. 2019 Jun;79(8):833-853. doi: 10.1007/s40265-019-01127-8.
8
Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole.解析药物性高血压：泊沙康唑非醛固酮依赖性激活盐皮质激素受体的分子机制
Clin Kidney J. 2018 Oct;11(5):688-690. doi: 10.1093/ckj/sfy087. Epub 2018 Sep 20.
9
Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.低剂量泊沙康唑治疗所致表观盐皮质激素过多综合征引起的难治性低钾血症
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.02605-17. Print 2018 Jul.
10
Posaconazole-Induced Pseudohyperaldosteronism.泊沙康唑致假性醛固酮增多症。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02130-17. Print 2018 May.
本文引用的文献
1
Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.服用缓释片与口服混悬液的患者中泊沙康唑血药浓度的回顾性比较
Antimicrob Agents Chemother. 2015 Aug;59(8):4914-8. doi: 10.1128/AAC.00496-15. Epub 2015 Jun 8.
2
Suspected posaconazole toxicity in a pediatric oncology patient.一名儿科肿瘤患者疑似泊沙康唑中毒。
Pediatr Blood Cancer. 2015 Sep;62(9):1682. doi: 10.1002/pbc.25568. Epub 2015 May 6.
3
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.泊沙康唑治疗对传统疗法难治或不耐受的侵袭性曲霉病患者：一项外部对照试验。
Clin Infect Dis. 2007 Jan 1;44(1):2-12. doi: 10.1086/508774. Epub 2006 Nov 28.
4
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.健康成年人单剂量和多剂量口服泊沙康唑的药代动力学、安全性及耐受性
Antimicrob Agents Chemother. 2003 Sep;47(9):2788-95. doi: 10.1128/AAC.47.9.2788-2795.2003.
Zotero 插件